

Outcomes of Septal Myectomy on Patients with Hypertrophic Cardiomyopathy

Caitlin Hoeing

Kaitlyn Kelly

Thomas Perillo

James K. Wu MD

Follow this and additional works at: <https://scholarlyworks.lvhn.org/research-scholars-posters>



Part of the **Cardiology Commons**

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Outcomes of Septal Myectomy on Patients with Hypertrophic Cardiomyopathy

Caitlin Hoeing, Kaitlin Kelly, Thomas Perillo, James Wu, MD
Division of Cardiothoracic Surgery

Lehigh Valley Health Network, Allentown, Pennsylvania

Background

- *Hypertrophic Cardiomyopathy* (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause
 - *Hypertrophy* = enlargement of tissue
- Drug-resistant patients → *Septal Myectomy*
 - Surgical removal of enlarged portions of the heart
- Previous studies have found promising outcomes that include low mortality rates and rare occurrences of major complications
 - Septal myectomy decreases symptoms of HCM




Figure 1: Diagram of HCM and Septal Myectomy Procedure

Objective

- This study seeks to evaluate the survival rates of patients with HCM that underwent the septal myectomy procedure.

Methods

- Classified
 - Single-center retrospective review of all septal myectomy patients from 2006-2020 at LVHN
- Reviewed
 - Specific patient data gathered and assessed through in-house database
 - Data was recorded in a unique REDCap database
- Analyzed
 - Descriptive statistics were used to analyze the significance of patient survival rates

Results

- 114 total patients
 - 14 died (12.28%)
 - Average survival time of 1134.14 days (3.10 years)
- 3 patients died within 30 days of the procedure (2.63%)
 - 2 died due to excessive bleeding
- Major complications were **not** prevalent in the population
 - Data is statistically significant, $p < 0.001$
- Survival rates are promising → only 12.28% died in a patient cohort that spans over 14 years

Factor	Number of events ^a		Number of censored ^b		Sample size
	N	%	N	%	
HCM Patients	14	12.28	100	87.72	114

Table 1: Septal Myectomy Patient Mortality Summary
Events = Death Censored = Alive




Figure 2: Kaplan-Meier Curve of Septal Myectomy Patients
The gradual drops in the curve illustrate promising survival rate for patients. The data suggests that this is statistically significant, $p < 0.001$.

Perioperative	Risk Factor	N	%
	CHF	51	44.7
Mitral Regurgitation	47	41.2	
LVOTO	46	40.4	
SAM	35	30.7	
AFib	24	21.1	
CAD	23	20.2	
Prior Pacemaker	18	15.8	
Dyspnea	12	10.5	
Postoperative	Complication	N	%
	New Pacemaker	10	8.7
Heart Block	8	7.0	
Kidney Failure	8	7.0	
New VSD Repair	5	4.4	
Extra Ventilator	3	2.6	
Excessive Bleeding	2	1.8	

Table 2: Pre-Septal Myectomy Risk Factors and Postoperative Complications

Conclusions

- Patients with several comorbidities are at **higher risk** for the septal myectomy procedure
 - However, the overall survival rates are promising
- Long-term survival rates of HCM patients that underwent septal myectomy illustrate **success** for this procedure
- Future research is encouraged to evaluate long-term outcomes of septal myectomy over 20 years and understand the effects of pre-TAVR risk factors

References

- Edwards, Anthony. "Transaortic Septal Myectomy: Techniques and Pitfalls." *Annals of Cardiothoracic Surgery*, www.annalscts.com/article/view/15789/15860.
- "Hypertrophic Cardiomyopathy." MedlinePlus, U.S. National Library of Medicine, medlineplus.gov/ency/article/000192.htm.
- Septal Myectomy, Johns Hopkins Medicine, www.hopkinsmedicine.org/health/treatment-tests-and-therapies/septal-myectomy.
- "Septal Myectomy." Cleveland Clinic, 6 May 2019, my.clevelandclinic.org/health/treatments/17461-septal-myectomy.